Vivesto ABOSTO:VIVE -3.40%26 Days Payable is 0.00 as of Mar. 2026. GuruFocus rates OSTO:VIVE with a GF Score™ of 26/100. The stock has 1 warning sign investors should review. Among 922 Drug Manufacturers companies, Vivesto AB ranks worse than 108459.76% on this metric.
The historical rank and industry rank for Vivesto AB's Days Payable or its related term are showing as below:
During the past 13 years, Vivesto AB's highest Days Payable was 2864.88. The lowest was 149.38. And the median was 321.97.
OSTO:VIVE's Days Payable is not ranked *
in the Drug Manufacturers industry.
Industry Median: 90.835 * Ranked among companies with meaningful Days Payable only.
Vivesto AB's Days Payable
stayed the same
from Mar. 2025 (0.00) to Mar. 2026 (0.00).
stayed the same
Vivesto AB Days Payable Related Terms
Vivesto AB Days Payable Historical Data
* Premium members only.
The historical data trend for Vivesto AB's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OSTO:VIVE vs ZTS, UTHR, VTRS: Days Payable Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Vivesto AB's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vivesto AB Days Payable vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Vivesto AB's Days Payable distribution charts can be found below:
* The bar in red indicates where Vivesto AB's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Vivesto AB's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vivesto AB (OSTO:VIVE) has a Days Payable of 0.00 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Vivesto AB and its competitors. Over the past decade, Vivesto AB's Days Payable has ranged from 149.38 to 2,864.88. According to the industry distribution chart, Vivesto AB ranks #999999 out of 922 companies in the Drug Manufacturers industry.
Is Vivesto AB's Days Payable too high?
Vivesto AB's current Days Payable is 0.00. Over the past 10 years, this metric has ranged from a low of 149.38 to a high of 2,864.88. Based on the distribution chart, Vivesto AB ranks #999999 out of 922 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Vivesto AB has a GF Score™ of 26/100, reflecting its overall financial health beyond just this single metric.
How does Vivesto AB's Days Payable compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Vivesto AB ranks #999999 out of 922 companies for Days Payable. This places Vivesto AB in the lower half of its industry. The industry median Days Payable is 90.84. Historically, Vivesto AB's own Days Payable has ranged from 149.38 to 2,864.88 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Drug Manufacturers company?
The median Days Payable among Drug Manufacturers companies is 90.84, based on 922 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Vivesto AB and its competitors. For the Drug Manufacturers industry, the median Days Payable is 90.84 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vivesto AB's current Days Payable is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vivesto AB stock overvalued right now?
Vivesto AB (OSTO:VIVE) has a current Days Payable of 0.00. The current Days Payable is 0.00. Vivesto AB's overall GF Score™ is 26/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Vivesto AB (OSTO:VIVE), the current Days Payable is 0.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Vivesto AB is a research and development company that develops new treatment options for patients suffering from difficult-to-treat cancer. The company's product development leverages its proprietary technology platforms to manufacture novel drug formulations that are intended to demonstrate improved properties in comparison with current alternatives, which can lead to a reduced side-effect profile and an expanded therapeutic area. The company has a portfolio of projects targeting cancer treatments.
26GF Score
Get the complete analysis for OSTO:VIVE
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSTO:VIVE has been successfully added to your 
